Literature DB >> 26268495

[Continuous positive airway pressure treatment for functional cardiac arrhythmias combined with obstructive sleep apnea hypopnea syndrome].

Liu Jianyong, Lu Jianbin, Li Menglin, Xu Yue, Yang Qi, Yuan Yifang, Yu Yan, Ye Jingying.   

Abstract

OBJECTIVE: To discuss the effect of continuous positive airway pressure (CPAP) treatment for functional cardiac arrhythmias combined with obstructive sleep apnea hypopnea syndrome.
METHODS: Fifty-six OSAHS patients combined functional cardiac arrhythmia were randomized divided into two groups. The 28 patients in the control group were treated with metoprolol according to cardiac guidelines, the other 28 cases in the experimental group were treated with CPAP therapy combined with metoprolol. AHI and the lowest oxygen saturation (LSaO2) were tested before and after treatment.
RESULTS: The efficiency rates were 57.1% and 17.9% in experimental and control group respectively, with statistical difference (χ2 = 7.62, P < 0.01). Total effective rates were 85.7% and 53.6% respectively, with statistical difference (χ2 = 5.41, P < 0.05). In the experimental group, there were three treatment subgroups. After treatment, AHI and the lowest oxygen saturation were significantly different (P < 0.05).
CONCLUSION: CPAP treatment can effectively eliminate respiratory disturbance index, improve the symptoms of hypooxygen at night, and effectively improve the therapeutic effect of functional cardiac arrhythmias in OSAHS patients combined with functional arrhythmia.

Entities:  

Mesh:

Year:  2015        PMID: 26268495

Source DB:  PubMed          Journal:  Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi        ISSN: 1673-0860


  1 in total

1.  Activating adenosine A1 receptor accelerates PC12 cell injury via ADORA1/PKC/KATP pathway after intermittent hypoxia exposure.

Authors:  Hong-Fang Mei; Neha Poonit; Yi-Chun Zhang; Chu-Yuan Ye; Hui-Lin Cai; Chen-Yi Yu; Yong-Hai Zhou; Bei-Bei Wu; Jun Cai; Xiao-Hong Cai
Journal:  Mol Cell Biochem       Date:  2018-01-29       Impact factor: 3.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.